BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 19117042)

  • 1. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?
    Forner A; Ayuso C; Varela M; Rimola J; Hessheimer AJ; de Lope CR; Reig M; Bianchi L; Llovet JM; Bruix J
    Cancer; 2009 Feb; 115(3):616-23. PubMed ID: 19117042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of tumor response on MR imaging after locoregional therapy.
    Vossen JA; Buijs M; Kamel IR
    Tech Vasc Interv Radiol; 2006 Sep; 9(3):125-32. PubMed ID: 17561215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer.
    Shuster A; Huynh TJ; Rajan DK; Marquez MA; Grant DR; Huynh DC; Jaskolka JD
    J Vasc Interv Radiol; 2013 Jun; 24(6):805-12. PubMed ID: 23562641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how?
    Meza-Junco J; Montano-Loza AJ; Liu DM; Sawyer MB; Bain VG; Ma M; Owen R
    Cancer Treat Rev; 2012 Feb; 38(1):54-62. PubMed ID: 21726960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of hepatocellular carcinoma locoregional therapies on patients waiting for liver transplantation.
    Moreno Planas JM; López Monclús J; Gómez Cruz A; Rubio González E; Pérez Arangüena R; Boullosa Graña E; Garcia Suárez A; Pérez-Picouto JL; Fernández Ruiz M; Lucena de la Poza JL; Sánchez Turrión V; Cuervas-Mons Martínez V
    Transplant Proc; 2005 Apr; 37(3):1484-5. PubMed ID: 15866648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results.
    de Baere T; Deschamps F; Teriitheau C; Rao P; Conengrapht K; Schlumberger M; Leboulleux S; Baudin E; Hechellhammer L
    J Vasc Interv Radiol; 2008 Jun; 19(6):855-61. PubMed ID: 18503899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead.
    Poon RT; Tso WK; Pang RW; Ng KK; Woo R; Tai KS; Fan ST
    Clin Gastroenterol Hepatol; 2007 Sep; 5(9):1100-8. PubMed ID: 17627902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation.
    Chapman WC; Majella Doyle MB; Stuart JE; Vachharajani N; Crippin JS; Anderson CD; Lowell JA; Shenoy S; Darcy MD; Brown DB
    Ann Surg; 2008 Oct; 248(4):617-25. PubMed ID: 18936575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A statistical simulation study finds discordance between WHO criteria and RECIST guideline.
    Mazumdar M; Smith A; Schwartz LH
    J Clin Epidemiol; 2004 Apr; 57(4):358-65. PubMed ID: 15135836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.
    Lencioni R; Llovet JM
    Semin Liver Dis; 2010 Feb; 30(1):52-60. PubMed ID: 20175033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Percutaneous radiofrequency ablation combined with transcatheter arterial chemoembolization and percutaneous ethanol injection for recurrent small hepatocellular carcinoma].
    Xu ZM; Wang JH; Zhen ZJ; Chen HW; Cui WZ
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Nov; 26(11):1626-8. PubMed ID: 17121718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional MR imaging as a new paradigm for image guidance.
    Assumpcao L; Choti M; Pawlik TM; Gecshwind JF; Kamel IR
    Abdom Imaging; 2009 Nov; 34(6):675-85. PubMed ID: 19048335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transarterial chemoembolization (TACE) for unresectable HCC: a new life begins?
    Biolato M; Marrone G; Racco S; Di Stasi C; Miele L; Gasbarrini G; Landolfi R; Grieco A
    Eur Rev Med Pharmacol Sci; 2010 Apr; 14(4):356-62. PubMed ID: 20496548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bland embolization of hepatocellular carcinoma using superabsorbent polymer microspheres.
    Osuga K; Hori S; Hiraishi K; Sugiura T; Hata Y; Higashihara H; Maeda N; Tomoda K; Nakamura H
    Cardiovasc Intervent Radiol; 2008; 31(6):1108-16. PubMed ID: 18543028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histopathologic outcome of neoadjuvant image-guided therapy of hepatocellular carcinoma.
    Marin HL; Furth EE; Olthoff K; Shaked A; Soulen MC
    J Gastrointestin Liver Dis; 2009 Jun; 18(2):169-76. PubMed ID: 19565046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma.
    Riaz A; Miller FH; Kulik LM; Nikolaidis P; Yaghmai V; Lewandowski RJ; Mulcahy MF; Ryu RK; Sato KT; Gupta R; Wang E; Baker T; Abecassis M; Benson AB; Nemcek AA; Omary R; Salem R
    JAMA; 2010 Mar; 303(11):1062-9. PubMed ID: 20233824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients.
    Malagari K; Chatzimichael K; Alexopoulou E; Kelekis A; Hall B; Dourakis S; Delis S; Gouliamos A; Kelekis D
    Cardiovasc Intervent Radiol; 2008; 31(2):269-80. PubMed ID: 17999110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology.
    Gordic S; Corcuera-Solano I; Stueck A; Besa C; Argiriadi P; Guniganti P; King M; Kihira S; Babb J; Thung S; Taouli B
    J Hepatol; 2017 Dec; 67(6):1213-1221. PubMed ID: 28823713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loco-regional treatment of hepatocellular carcinoma in the era of molecular targeted therapies.
    Lencioni R
    Oncology; 2010 Jul; 78 Suppl 1():107-12. PubMed ID: 20616592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local ablative therapies in HCC: percutaneous ethanol injection and radiofrequency ablation.
    Mahnken AH; Bruners P; Günther RW
    Dig Dis; 2009; 27(2):148-56. PubMed ID: 19546553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.